TherapeuticsMD swings to Q3 profit, license revenue climbs

Reuters

Nov 13, 2025

TherapeuticsMD swings to Q3 profit, license revenue climbs

Overview

TherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last year
License revenue for Q3 rises due to changes in sales of licensed products
Company exploring strategic alternatives, no assurance of transaction outcome

Outlook

TherapeuticsMD is evaluating strategic alternatives, including mergers or asset sales
Company has not set a timetable for strategic evaluations

Result Drivers

LICENSE REVENUE INCREASE - License revenue rose due to changes in sales of licensed products
OPERATING EXPENSES - Operating expenses decreased by 2.1% compared to Q3 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income from Cont Ops		$50,000
Q3 Operating Expenses		$1.65 mln

Press Release: ID:nBw8Hlscxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583583976"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583583976\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583583976?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583583976","market":"nz","top_or_hot":-1,"title":"TherapeuticsMD swings to Q3 profit, license revenue climbs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>TherapeuticsMD swings to Q3 profit, license revenue climbs</title></head><body><p><span>Overview</span></p><ul><li><p>TherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last year</p></li><li><p>License revenue for Q3 rises due to changes in sales of licensed products</p></li><li><p>Company exploring strategic alternatives, no assurance of transaction outcome</p></li></ul><p><span>Outlook</span></p><ul><li><p>TherapeuticsMD is evaluating strategic alternatives, including mergers or asset sales</p></li><li><p>Company has not set a timetable for strategic evaluations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LICENSE REVENUE INCREASE - License revenue rose due to changes in sales of licensed products</p></li><li><p>OPERATING EXPENSES - Operating expenses decreased by 2.1% compared to Q3 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income from Cont Ops</p></td><td></td><td><p>$50,000</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$1.65 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw8Hlscxa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TherapeuticsMD swings to Q3 profit, license revenue climbs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTherapeuticsMD swings to Q3 profit, license revenue climbs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>TherapeuticsMD swings to Q3 profit, license revenue climbs</title></head><body><p><span>Overview</span></p><ul><li><p>TherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last year</p></li><li><p>License revenue for Q3 rises due to changes in sales of licensed products</p></li><li><p>Company exploring strategic alternatives, no assurance of transaction outcome</p></li></ul><p><span>Outlook</span></p><ul><li><p>TherapeuticsMD is evaluating strategic alternatives, including mergers or asset sales</p></li><li><p>Company has not set a timetable for strategic evaluations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LICENSE REVENUE INCREASE - License revenue rose due to changes in sales of licensed products</p></li><li><p>OPERATING EXPENSES - Operating expenses decreased by 2.1% compared to Q3 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income from Cont Ops</p></td><td></td><td><p>$50,000</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$1.65 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw8Hlscxa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXMD","symbol_name":"TherapeuticsMD Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO13F:1","article_id":"2583583976","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583583976","pubTimestamp":1762982693,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TherapeuticsMD swings to Q3 profit, license revenue climbsOverviewTherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last yearLicense revenue for Q3 rises due t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXMD":"TherapeuticsMD Inc.","BK4007":"制药"},"translate_title":"TherapeuticsMD第三季度盈利，许可收入攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXMD":0.9},"content_text":"TherapeuticsMD swings to Q3 profit, license revenue climbsOverviewTherapeuticsMD reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last yearLicense revenue for Q3 rises due to changes in sales of licensed productsCompany exploring strategic alternatives, no assurance of transaction outcomeOutlookTherapeuticsMD is evaluating strategic alternatives, including mergers or asset salesCompany has not set a timetable for strategic evaluationsResult DriversLICENSE REVENUE INCREASE - License revenue rose due to changes in sales of licensed productsOPERATING EXPENSES - Operating expenses decreased by 2.1% compared to Q3 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income from Cont Ops$50,000Q3 Operating Expenses$1.65 mlnPress Release: ID:nBw8HlscxaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}